Maxime Verhoeven

95 TCZ vs. TCZ+MTX; prevention of radiographic progression in RA Supplementary Figure S1 Relative chance of preventing radiographic progression in early RA.* Number of patients in low level baseline joint damage subgroup; 160 in TCZ vs. 166 in TCZ+MTX, number of patients in high level baseline joint damage subgroup; 129 in TCZ vs. 132 in TCZ+MTX. Number of patients in low level baseline DAS28 subgroup; 149 in TCZ vs. 145 in TCZ+MTX, number of patients in high level baseline DAS28 subgroup; 146 in TCZ vs. 153 in TCZ+MTX. *Relative chances (95%CI) are based on stratified analyses, controlling for age, gender and DAS28 at baseline. A RR above 1 is associated with less radiographic progression for TCZ. Low/high levels of baseline joint damage (SvdH score ≤1/>1) or disease activity (DAS28 ≤6.37/>6.37) were based on their respective median values in the data. RA= rheumatoid arthritis; SvdH= Sharp van der Heijde; TCZ= tocilizumab; MTX= methotrexate; RR= relative chance; % Ref= proportion of patients with no progression (i.e., based on raw data) in the reference group, i.e., TCZ+ MTX group. 5